Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179066 | 1.00 | CYP1A2 (0.65) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL2891211 | 0.91 | CYP1A2 (0.55) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL9949471 | 0.90 | TSHR (0.55) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL9949467 | 0.90 | TSHR (0.55) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL5295954 | 0.90 | CYP1A2 (0.54) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL27000220 | 0.86 | CYP1A2 (0.51) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL26733039 | 0.85 | KMT2A (0.49) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL27865745 | 0.83 | CYP1A2 (0.48) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL27000088 | 0.81 | MAPK1 (0.51) | CYP1A2KMT2ASMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL2909287 | 0.81 | MAPT (0.50) | CYP1A2KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | claimed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CYP1A2 2152/4885KMT2A 611/4885SMN1; SMN2 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.